Literature DB >> 2033265

Induction of protective immunity to Friend murine leukemia virus in genetic nonresponders to virus envelope protein.

C Ishihara1, M Miyazawa, J Nishio, B Chesebro.   

Abstract

(B10.A x A/WySn)F1, H-2a/a, mice are genetic nonresponders to the envelope protein of Friend murine leukemia helper virus (F-MuLV) when immunized with a recombinant vaccinia virus expressing F-MuLV env gene. In contrast these mice can be protectively immunized against leukemogenic Friend virus complex using formalin-fixed F-MuLV virions in CFA. To determine which viral proteins were responsible for this immune protection, virion proteins prepared by SDS-PAGE and electroelution were used to immunize mice. Purified gp70 envelope protein in CFA was capable of inducing strong immune protection against the challenge with Friend virus complex in H-2a/a mice. Immunologic studies demonstrated that immunized mice developed a virus-specific T cell proliferative response and showed IgM to IgG Ig class switching of virus-neutralizing antibodies. These results indicated that genetically controlled immune nonresponsiveness to F-MuLV envelope Ag in H-2a/a mice could be overcome using denatured viral envelope protein together with a strong adjuvant.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033265

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.

Authors:  Wibke Bayer; Matthias Tenbusch; Ruth Lietz; Lena Johrden; Simone Schimmer; Klaus Uberla; Ulf Dittmer; Oliver Wildner
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

Review 2.  Immunity to retroviral infection: the Friend virus model.

Authors:  K J Hasenkrug; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  Immunogenic determinants of a neuropathogenic murine leukemia virus.

Authors:  D S Robbins; M P Remington; M Sarzotti; D St Louis; P M Hoffman
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

4.  Lymphocyte deficiencies increase susceptibility to friend virus-induced erythroleukemia in Fv-2 genetically resistant mice.

Authors:  K J Hasenkrug
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Class switch recombination and somatic hypermutation of virus-neutralizing antibodies are not essential for control of friend retrovirus infection.

Authors:  Maiko Kato; Sachiyo Tsuji-Kawahara; Yuri Kawasaki; Saori Kinoshita; Tomomi Chikaishi; Shiki Takamura; Makoto Fujisawa; Akira Kawada; Masaaki Miyazawa
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

Review 6.  Humoral immunity in the Friend retrovirus infection model.

Authors:  Kalani Halemano; Michael S Harper; Kejun Guo; Sam X Li; Karl J Heilman; Bradley S Barrett; Mario L Santiago
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

7.  Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene.

Authors:  M Miyazawa; J Nishio; B Chesebro
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

8.  Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice.

Authors:  M N Robertson; G J Spangrude; K Hasenkrug; L Perry; J Nishio; K Wehrly; B Chesebro
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

9.  Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms.

Authors:  U Dittmer; D M Brooks; K J Hasenkrug
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

10.  Requirement for CD4(+) T cells in the Friend murine retrovirus neutralizing antibody response: evidence for functional T cells in genetic low-recovery mice.

Authors:  H J Super; D Brooks; K Hasenkrug; B Chesebro
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.